Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen

NCT00291837 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00291837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00291837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
December 31, 2007
Enrollment
40
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer